Results for tag: "Histone Deacetylase Inhibitor"

Histone Deacetylase Inhibitors (HDACIs) are a class of drugs used to treat diseases of the Central Nervous System (CNS). HDACIs are used to treat a variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. HDACIs work by blocking the activity of histone deacetylases, enzymes that regulate gene expression. By blocking these enzymes, HDACIs can reduce inflammation and improve cognitive function. HDACIs are a relatively new class of drugs, and the market is still in its early stages. However, the potential of HDACIs to treat a variety of neurological disorders has attracted the attention of many pharmaceutical companies. Several companies are currently developing HDACIs for the treatment of CNS diseases, including Merck, Pfizer, Novartis, and AstraZeneca. Additionally, several biotechnology companies are researching HDACIs for the treatment of neurological disorders, including AbbVie, Biogen, and Genentech. Show Less Read more